SPLENDOR lead author Ali Amirian, the Surfers, and audience member Shardool Jain of Altrix Bio debate whether and when bariatric surgery might become first-line therapy for multi-morbid metabolic patients.
Dr. Jain takes the position that for many patients with metabolic comorbidities, drugs tends not to work over time, so why not go to bariatric earlier in therapy…even in first line? Panelists disagree to varying degrees. After Dr. Jain leaves, the group answers Roger’s question about what they anticipate might be long-acting effects of this pivotal study.